10/549323

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Frank STRIGGOW et al.

2005 Rec'd PCT/PTO 1 6 SEP 2005

Title:

Use of Incense or Hydrogenation Products for Preventing

and/or Treating a Cerebral Ischemia and/or Cerebral

Traumatic Lesion

Appl. No.:

Not Assigned

(National Phase of PCT/EP04/02839)

National Phase

September 16, 2005

Filing Date:

Examiner:

Not Assigned

Art Unit:

Not Assigned

Atty Docket No: LNK-007

INFORMATION DISCLOSURE STATEMENT

MAIL STOP AMENDMENT

Honorable Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. Accordingly, no certification or fee is required.

National Phase Entry for PCT/EP04/02839

Atty Docket No.: LNK-007
JC05 Rec'd PCT/PTO 1 6 SEP_2009

Note, the documents listed in the Form PTO-1449 were cited during the international phase of prosecution of the instant application. Copies of the foreign patent and non-patent literature references are enclosed herewith along with a copy of the international search report. However, in accordance with the revised procedures under 37 CFR 1.98(a)(2)(i), copies of the cited U.S. patent references have not been provided.

In accordance with 37 C.F.R. §§ 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search had been made or that information cited is, or is considered to be, material to patentability as defined in 37 C.F.R.§ 1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item, and Applicant reserves the right to prove that the date of publication is in fact different.

The Commissioner is authorized to charge any deficiency in any fees pursuant to 37 CFR § 1.17 associated with this communication and to credit any excess payment to Deposit Account No. 50-2101.

Respectfully submitted,

Date: 09/16/05

SMITH PATENT CONSULTING, LLC P.O. Box 2726 Alexandria, VA 22301

Tel: 703-549-7691 Fax: 703-549-7692 Name: Chalin A. Smith Title: Attorney for Applicant Registration No. 41,569

CUSTOMER NUMBER 31496

JC05 Rec'd PCT/PTO 16 SEP 2003

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)				ATTY. DOCK LNK-007	(National Pl PCT/EP04/(SERIAL NO. Not Assigned (National Phase of PCT/EP04/02839) 7549323		
	•	,		APPLICANT F. STRIGGO	OW et al.			
				NATIONAL PHASE FILING DATE September 16, 2005		GROUP Not Assigned		
		U.	S. PATENT I	OCUMENTS	· · · · · · · · · · · · · · · · · · ·	<u> </u>	<u> </u>	
EXAMINER'S INITIALS	PATENT NO.	DATE		NAME		ŞUBCLASS	FILING	DATE
	5,720,975	02-24-98	Etzel	,	424	464		
	6,280,751	08-28-01	Fletcher et al.		424	401		
		_			_		· - ·	
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY/APPLICANT		CLASS	SUBCLASS	Translation	
	ļ						ļ	
							ļ	-
		-				 		
							-	
	OTHI	ED ADT (Inclu	ding Author	Fitle, Date, Perti	nant Pages Et	<u> </u>		
				CT/EP04/0283		····		
	Wang, W, W		No. XP-0022	91633, Derwe	nt Publicatio	ns Ltd. (199	5) -	
	Kreck, C. et a	ıl., Versicheri	ıngsmedizin	E.V. 1, Vol. 5	1, No. 3, pp.	122-127 (19	999)	
	Safayhi, H. et	al., Pharmaz	eutische Zei	tung, Vol. 142	, No. 39, pp.	11-20 (1999))	
						•		
						•		
				•				
EXAMINER	DATE CONSIDERED							

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.